Compare BridgeBio Pharma Inc (BBIO) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Royal Bank of Canada — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Royal Bank of Canada trades at $215.06 (market cap $291.56B). The key difference: Royal Bank of Canada is far larger — about 17.9× BridgeBio Pharma Inc's market cap, and Royal Bank of Canada pays a 2.42% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | RY | |
|---|---|---|
Market Cap | $16.27B | $291.56B |
Sector | Health | Financials |
52-Week High | $90.17 | $214.04 |
52-Week Low | $44.81 | $128.46 |
Enterprise Value | $17.82B | — |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
